Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
EXCLUSIVE FORMULATION STUDY COLLABORATION WITH PAR STERILE PRODUCTS TO DEVELOP A STABLE READY TO USE PRODUCT
Cambridge, UK, 7th June 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study agreement with Par Sterile Products, LLC, an Endo International plc company (“Par”).
Under this agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated, stable,…
Click here to view the June 2021 edition of eNews - an ON Helix preview.
Cambridge, UK: 08 June 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes bringing connections to expert advisers and business intelligence sources to enable members to create their corporate development plans from a position of knowledge. PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For nearly 30…
Uppsala, Sweden June 7th 2021, - LINK Medical, a full-service contract research organization (CRO) providing product development and post-marketing services for the pharmaceutical and medical device industries, has signed a contract to join forces with Insife, an expert consulting and technology service provider for safety and pharmacovigilance organizations.
This partnership combines extensive experience and know-how from LINK Medical with a robust, enabling technology from Insife, providing LINK Medical with a top-of-the line safety database and other powerful supporting modules.
A fully-…
In this special edition of PharmaVentures Insights, Dr Fintan Walton, CEO & Founder of PharmaVentures, leads a panel discussion to address whether a dual fundraising and partnering strategy is the best way forward for an emerging biotech.
Panelists include Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist Search and Evaluation at Novo Nordisk, Jeanne Bolger, Vice President, Venture Investments at Johnson & Johnson Innovation, Bart Dzikowski, Managing Director, Head of Transactions & Legal at Novartis Venture Fund, Tim…
Transine Therapeutics (‘Transine’), a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP® platform technology, announces that it successfully secured £9.1 million in seed funding. The financing was co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund (DDF), and will enable Transine to further develop its proprietary platform towards building a pipeline of novel mRNA-targeted therapeutics initially focused on the Central Nervous System and Ophthalmology applications.
Transine is based on the pioneering work of world-renowned geneticists…
Cambridge, UK: 1st June 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes providing members with opportunities to reduce operating costs without compromising their choice or independence. The One Nucleus Group Purchasing Scheme saves members over £3M per annum via negotiated Preferred Supplier Agreements. 001 Limited, a leader in Business Utility Services, Electricity, Gas, Telecommunications,…
Cambridge, UK: 27 May 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge, exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes promoting and leveraging the world class excellence within our network by facilitating the right connections. Charles River, a global leader in drug discovery and development has become the latest company to join the One Nucleus Partner Programme. The programme is tailor-made to meet the needs of the Partner and One…
AMSBIO reports upon a publication** that cites how its STEM-CELLBANKER® animal-free cryopreservation media has played a role in the development of a cell therapy for Parkinson’s Disease that will soon be going into clinical trials.Parkinson’s disease is one of the most common neurodegenerative diseases worldwide. Its main features include motor symptoms such as bradykinesia, rigidity, resting tremor, and postural instability, though non-motor symptoms are often also present. Currently the main therapy for Parkinson's disease consists of augmentation of dopamine levels…
Alderley Park, Cheshire Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and ADA analysis of Infex’s RESP-X program.
RESP-X is an anti-virulence therapy in-licensed from Japanese pharma company Shionogi. It is designed to help the body tackle Pseudomonas aeruginosa infections, a hard to treat drug-resistant pathogen recognised by the WHO as a critical threat to human health. A novel humanised monoclonal antibody, RESP-X does not kill bacteria directly but deactivates a mechanism that prevents the immune system from acting against the infection.
Dr Peter…